Thymosin alpha 1 prescription access in the US is limited because the peptide is not FDA-approved. Here's how people get it, plus risks and legal facts.
There is no FDA-approved thymosin alpha 1 prescription product in the United States. The peptide is licensed as a medicine in more than 30 other countries under the brand name Zadaxin, but the FDA has never cleared it for human use, so any vial sold to a US buyer is an unapproved compounded preparation, a research chemical labeled "not for human consumption," or an imported drug.
That distinction matters. It changes who can legally supply it, what is actually inside the vial, and how much legal protection you have if something goes wrong.
Is Thymosin Alpha 1 Legal to Buy With a Prescription in the US?
Thymosin alpha 1, also called thymalfasin, is a synthetic 28-amino-acid peptide that copies a hormone produced by the thymus gland. It is approved in Italy, China, India, the Philippines, and other markets as an immune-modulating adjunct for chronic hepatitis B and C and certain cancers.
The FDA has not approved it for any indication. There is no approved label, no US manufacturer, and no new drug application on file. A US clinician therefore cannot write a prescription for an FDA-approved version, because no such version exists.
Two narrow paths exist on paper. The FDA's personal importation guidance permits small quantities of unapproved drugs for personal use in limited cases, usually with a prescription and a 90-day supply limit, but peptide shipments are frequently detained. Compounding is the other route, and it is restricted: pharmacies operating under section 503A may only use bulk drug substances the FDA has cleared, and thymosin alpha 1 is not cleared for routine compounding.
How People Actually Get Thymosin Alpha 1 in the US
Access today runs through four channels, and they are not equal in quality or legal risk.
| Source | What you receive | Legal status | Typical cost |
|---|---|---|---|
| US telehealth clinic | Compounded vial via a partner pharmacy | Unsettled; FDA has challenged peptide compounding | $100–$400 per month |
| Overseas online pharmacy | Branded Zadaxin 1.6 mg vials | Personal importation gray area; seizures occur | $300–$600 per course |
| Research chemical vendor | Lyophilized powder marked "not for human consumption" | Legal as a lab reagent; human use is not | $40–$120 per vial |
| Clinical trial | Investigational product plus monitoring | Fully legal; eligibility is limited | $0 |
The cheapest option carries the most risk. Research-grade powder is not manufactured to sterile-injectable standards, and independent testing has repeatedly found peptides that are underdosed, contaminated, or simply not the peptide on the label.
If you want a legal, supervised option, ask a physician about clinical trials rather than buying from a website.
Why the FDA Has Never Approved It
Sponsors have tested thymosin alpha 1 in sepsis, hepatitis, and oncology, and the results have been mixed. A large Phase 3 sepsis trial in Italy was complicated by data-integrity questions, and no sponsor has completed the large, well-controlled US studies the FDA requires for approval.
Unapproved does not automatically mean unsafe or ineffective. It does mean that no regulator has verified the purity, potency, or manufacturing standards of the product you might buy.
What Thymosin Alpha 1 Protocols Look Like in Published Research
Anyone asking what is thymosin alpha 1 usually wants to know how it is used. In the medical literature, the dose is remarkably consistent: 1.6 mg injected subcutaneously, once or twice weekly, for weeks to months depending on the condition being studied.
| Setting | Dose studied | Frequency | Duration |
|---|---|---|---|
| Chronic hepatitis B | 1.6 mg SC | Twice weekly | 6 months |
| Chronic hepatitis C (adjunct) | 1.6 mg SC | Twice weekly | 6–12 months |
| Severe infection or sepsis (investigational) | 1.6 mg SC | Twice daily for 5 days, then daily for 5 days | 10 days |
| Immune-support protocols in community use | 1.6 mg SC | Once or twice weekly | 4–12 weeks |
A thymosin alpha 1 dosage chart like this one summarizes research protocols, not prescribing instructions. No US guideline endorses these doses, and a licensed clinician should set any actual treatment plan.
Thymosin Alpha 1 vs Thymosin Beta 4 vs Thymalin
The names sound interchangeable, but these are different molecules studied for different reasons.
| Peptide | Structure | Main research focus | US prescription status |
|---|---|---|---|
| Thymosin alpha 1 | 28-amino-acid synthetic peptide | T-cell maturation and immune modulation | Not approved |
| Thymosin beta 4 | 43-amino-acid peptide found in most cells | Actin regulation, wound healing, tissue repair | Not approved |
| Thymalin | Polypeptide extract from bovine thymus | Immune support in older adults, mostly in Russian studies | Not approved |
A direct thymosin alpha 1 vs thymosin beta 4 comparison comes down to mechanism: one targets immune signaling, the other targets cell migration and repair. When researchers weigh thymalin vs thymosin alpha 1, the deciding factor is usually that Thymalin is an animal-tissue extract while thymosin alpha 1 is a single synthesized peptide.
Safety and Sourcing Questions Worth Asking
Reported side effects in trials are usually mild: injection-site reactions, fatigue, low-grade fever, and occasional nausea. Serious allergic reactions are uncommon but possible, especially with repeated injections.
People who look into thymosin alpha 1 when sick often want a quick immune boost during an infection. No US guideline recommends that use, and self-treating a serious infection with an unapproved injectable can delay effective care.
Before buying from any supplier, ask these questions:
- Was the vial produced in a facility inspected by a recognized regulator?
- Is there a third-party certificate of analysis tied to a specific lot number?
- Is the product labeled for research only or for human use?
- Will the seller provide a written invoice, a return address, and contact information?
Few online sellers can answer all four. Thymosin alpha 1 is not FDA-approved for human use in the United States, and a healthcare professional should be involved in any decision to use it.
Frequently Asked Questions
Can I get a thymosin alpha 1 prescription in the US?
Not through a standard pharmacy. Because thymosin alpha 1 is not FDA-approved, there is no approved product for a US pharmacy to dispense, and the FDA has not cleared the peptide for routine compounding under section 503A. Some telehealth clinics pair patients with compounding pharmacies anyway, but the legal footing is unsettled.
Is thymosin alpha 1 the same as Zadaxin?
Yes. Zadaxin is the brand name for thymalfasin, which is the pharmaceutical name for thymosin alpha 1. It is approved in more than 30 countries, including Italy, China, and India, but it has never been approved in the United States.
What is the typical thymosin alpha 1 dose?
Most published studies use 1.6 mg injected subcutaneously once or twice per week, with durations ranging from a few weeks to six months or longer. Those are research doses rather than FDA-approved prescribing guidance, and any real treatment plan should come from a licensed clinician.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.